Advertisement

Menopausal Hormone Therapy and breast cancer risk: Individualization is the key to safety

      Menopausal hormone therapy (MHT) is the treatment of choice for climacteric and particularly vasomotor symptoms [
      • Armeni E.
      • Lambrinoudaki I.
      • Ceausu I.
      • Depypere H.
      • Mueck A.
      • Pérez-López F.R.
      • Schouw Y.T.
      • Senturk L.M.
      • Simoncini T.
      • Stevenson J.C.
      • Stute P.
      • Rees M.
      Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).
      ]. Current guidelines advise that treatment should be individualized according to the characteristics of the patient, including cardiovascular and cancer risk assessment. In general, combined therapy with estrogen and a progestogen is indicated for women with an intact uterus, whereas estrogen monotherapy is considered for hysterectomized women. [
      • Armeni E.
      • Lambrinoudaki I.
      • Ceausu I.
      • Depypere H.
      • Mueck A.
      • Pérez-López F.R.
      • Schouw Y.T.
      • Senturk L.M.
      • Simoncini T.
      • Stevenson J.C.
      • Stute P.
      • Rees M.
      Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).
      ]
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Armeni E.
        • Lambrinoudaki I.
        • Ceausu I.
        • Depypere H.
        • Mueck A.
        • Pérez-López F.R.
        • Schouw Y.T.
        • Senturk L.M.
        • Simoncini T.
        • Stevenson J.C.
        • Stute P.
        • Rees M.
        Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).
        Maturitas. 2016; 89: 63-72
        • Manson J.E.
        • Aragaki A.K.
        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • LaCroix A.Z.
        • et al.
        Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials.
        Jama. 2017; 318: 927-938
        • Chlebowski R.T.
        • Rohan T.E.
        • Manson J.E.
        • Aragaki A.K.
        • Kaunitz A.
        • Stefanick M.L.
        • et al.
        Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials.
        JAMA oncology. 2015; 1: 296-305
        • Beral V.
        Breast cancer and hormone-replacement therapy in the Million Women Study.
        Lancet. 2003; 362: 419-427
        • Fournier A.
        • Berrino F.
        • Clavel-Chapelon F.
        Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
        Breast cancer research and treatment. 2008; 107: 103-111
        • Fournier A.
        • Berrino F.
        • Riboli E.
        • Avenel V.
        • Clavel-Chapelon F.
        Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort.
        International journal of cancer. 2005; 114: 448-454
        • Collaborative Group on Hormonal Factors in Breast C
        Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
        Lancet. 2019; 394: 1159-1168
        • Chlebowski R.T.
        • Anderson G.L.
        • Aragaki A.K.
        • Manson J.E.
        • Stefanick M.L.
        • Pan K.
        • et al.
        Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials.
        JAMA. 2020; 324: 369-380
        • Gompel A.
        • Plu-Bureau G.
        Progesterone, progestins and the breast in menopause treatment.
        Climacteric. 2018; 21: 326-332
        • Lambrinoudaki I.
        Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
        Maturitas. 2014; 77: 311-317
        • Trabert B.
        • Sherman M.E.
        • Kannan N.
        • Stanczyk F.Z.
        Progesterone and Breast Cancer.
        Endocr Rev. 2020; 41: 320-344